ELCC Wrap Up

Episode
61
Soundcloud
Share

This edition of Lung Cancer Considered discusses important science presented at the recently completed European Lung Cancer Congress, the multidisciplinary lung cancer meeting co-organized by ESMO and IASLC. Dr. Enriqueta Felip and Dr. Fabrice Barlesi share their interpretation of the following clinical trials presented at ELCC:

  • Adagrasib (MRTX849) -- phase Ib expansion and phase II monotherapy cohorts
  • CheckMate 9LA -- randomized 719 patients with EGFR/ALK wild type NSCLC to standard chemotherapy or 2 cycles of chemotherapy with nivolumab and Ipilimumab
  • KEYNOTE-407-- randomized squamous NSCLC to carboplatin with choice of nab/ paclitaxel or paclitaxel, and either pembrolizumab or placebo
  • AMG 757-- BiTE: bispecific T-cell engager targeting DLL3 and engaging CD3
  • CAMEL-sq trial-- phase III randomized trial in patients with advanced squamous NSCLC

Other Podcast